It's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. BTIG analyst ...

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of ...

Merck (NYSE: MRK) shares decreased in price Friday, on word the European Medicines Agency's Committee for Medicinal Products ...

In a recent study published in Nature, University of Pennsylvania scientists investigated a novel approach for treating ...

Atherosclerosis involves multiple processes including endothelial dysfunction, inflammation, vascular proliferation and matrix alteration. Vascular proliferation contributes to the pathobiology of ...

The drug candidate is administered through the intravitreal route. It is a soluble fusion protein comprising of vascular endothelial growth factor receptor 3 (VEGFR-3) fused to the Fc fragment of ...

The European Medicines Agency (EMA) has approved Roche’s Vabysmo (faricimab) in single-dose prefilled syringe form for three ...

Hope for a much-needed treatment for the common pregnancy complication pre-eclampsia has been raised by a successful test of ...

Separately, upon receipt of the full efficacy and safety results for the NORSE EIGHT clinical trial in the United States, which are expected in January 2025, Outlook Therapeutics plans to resubmit its ...

Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...

Vabysmo is a bispecific antibody approved for the eye. It targets and inhibits two signalling pathways linked to a number of ...